Navigation Links
Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial

OXFORD, England, September 27, 2011 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive phase II clinical results showing that its ToleroMune® hay fever vaccine substantially improved patients' allergy symptoms compared with those on placebo.  The treatment was extremely well tolerated.  

During the randomised, double-blind, placebo-controlled phase II study conducted in 50 hay fever sufferers in Quebec, Canada, patients received four doses from one of five different treatment regimes over a 12-week period.  Five weeks later, investigators tested the patients' skin and eye responses to grass pollen.  The results show that the treatment reduced allergic symptoms in patients' eyes by up to 30% more than placebo.  In addition, the therapy improved early and late skin reactions by up to 54% and 19% above placebo respectively.  The ToleroMune T-cell vaccine had a similar safety profile to placebo.

Following these results, Circassia has initiated the final phase II trial of its hay fever treatment.  The double-blind, placebo-controlled study is underway in Kingston, Canada in 280 volunteers, and will assess the effectiveness of the ToleroMune T-cell vaccine at improving patients' nasal symptoms and eye responses when exposed to grass pollen in an exposure chamber.  

"Achieving these clinical results is particularly encouraging as hay fever is an extremely common allergy, which can have a major impact on sufferers," said Steve Harris, Circassia's CEO.  "Many current therapies provide short-term symptom relief only, while traditional immunotherapies can require specialist treatment over several years to address the underlying disease.  Circassia's latest results follow earlier successful studies in a range of different allergies.  Our clinical data show that Circassia's T-cell vaccines have the potential to revolutionise allergy therapy, and these recent results give us the confidence to proceed with the final phase II testing of our unique hay fever treatment."

About Circassia's allergy T-cell vaccines

Circassia is developing a range of allergy T-cell vaccines based on its proprietary ToleroMune® technology.  The company has successfully completed a number of phase II studies with its cat, house dust mite, ragweed and grass allergy therapies.  Clinical results show that short treatment regimes with Circassia's T-cell vaccines can greatly reduce patients' allergic responses, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated.  As a result, the treatments offer major potential clinical benefits compared with existing therapies, and have significant market opportunities.  Over 150 million people suffer from allergic rhinitis in the US and Europe, and approximately 15% - 25% of people in these countries are sensitive to grass pollen.  As a result, the current allergy treatment market is valued at approximately $12 billion per year.  

About Circassia

Circassia was founded in 2006 by a team of highly experienced biotechnology scientists and entrepreneurs, and is chaired by the former Chairman of GlaxoSmithKline, Sir Richard Sykes.  The company is based in the UK on the Oxford Science Park, and in Hamilton, Canada, where its joint venture Adiga Life Sciences is located.  Its ToleroMune technology was developed originally by scientists at Imperial College, London.  Having successfully completed four fundraising rounds, Circassia has raised approximately £93 million ($159 million) and is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations and Invesco Perpetual.

Steve Harris
Tel: +44 (0)1865 784574

Rob Budge
RJB Communications
Tel: +44 (0)1865 760969
Mobile: +44 (0)7710 741241

SOURCE Circassia
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lactobacillus Beverage Confirmed to Reduce Fever Brought on by Acute Gastroenteritis Caused by Norovirus Infection
2. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
3. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
4. Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients
5. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
6. Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
7. Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment
8. The New Face of Personalized Medicine: Targeting Disease Diagnostics and Treatments with Big Data Analytics: October 6, 2011, 1 PM EDT, Webinar
9. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
10. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
11. New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients Functionality and Quality of Life
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... ... 2015 , ... International Society for Pharmaceutical Engineering (ISPE) closed ... events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in Philadelphia, ... number of attendees in more than a decade. , “The 2015 Annual ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
Breaking Biology News(10 mins):